BiomX Inc. (PHGE): M&A transaction — BiomX deconsolidates Israel subsidiary after insolvency proceedings

BiomX Inc.

BiomX Ltd. (wholly owned subsidiary) filed for insolvency in Israel on Jan 25, 2026; trustee appointed.
CEO Jonathan Solomon and CFO Marina Wolfson terminated as officers of BiomX Ltd. retroactive to Jan 25 (remain at parent).
Company deconsolidated BiomX Ltd. effective Feb 4, 2026, deemed a significant disposition of assets.
Pro forma shows cash of $5.4M, accumulated deficit of $205.6M; net loss for 9M 2025 reduced from $22.9M to $5.9M.
Severance payments: 9 months for CEO, 6 months for CFO and CDO.

item 2.01 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.4

BiomX Inc. completed a disposition involving Trustee (closed 2026-02-04).

Action: disposition
Counterparty: Trustee
Closing: 2026-02-04

Exact text from the filing

On February 4, 2026, the Trustee notified BiomX Ltd.’s Chief Executive Officer and Chief Financial Officer that their roles as officers of BiomX Ltd. had been terminated. The Company determined that the termination is considered as a change of control as of February 4, 2026, and that BiomX Ltd. should be deconsolidated from the Company’s consolidated financial statements. The deconsolidation of BiomX Ltd. is considered a disposition of a significant amount of assets under Item 2.01 of Form 8-K.

View on SEC.gov

15 m&a transactions filed in the last 30 days. Browse all m&a transactions →

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-014298

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.